Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05515562 · ClinicalTrials.gov registry record · Phase 4

Effects of Intravenous (IV) Omadacycline on Gut Microbiome

A Phase 4 study of Microbial Colonization, sponsored by Wake Forest University Health Sciences.

Completed
Registry status
Phase 4
Development phase
8
Enrollment target
1
Study location

NCT05515562: Completed Phase 4 study of Microbial Colonization, sponsored by Wake Forest University Health Sciences.

NCT05515562 is a Phase 4 study of Microbial Colonization that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 8 participants, below the 12,654-participant average among 20 other Microbial Colonization trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05515562, a Phase 4 study of Microbial Colonization, has completed, sponsored by Wake Forest University Health Sciences.

COMPLETED
Registry status
Phase 4
Development phase
8 participants
Enrollment target
1
Study location

Study Summary

Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteers.

Primary Outcome

In general, the healthy volunteer analyses will assess changes in total and species-specific microbiota over time as well as changes in microbial diversity.

Conditions Studied

Interventions

  • DRUG Omadacycline Injection

Study Locations (1)

North Carolina

  • Wake Forest Baptist Health - Winston-Salem

Trial Details

FieldValue
Enrollment Target 8 participants
Start Date 2023-03-20
Est. Completion 2023-07-11
Phase Phase 4
Wake Forest University Health Sciences

1,140 total trials

What the finished NCT05515562 record still lists

NCT05515562 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 8 participants, a relatively small participant target, below the 12,654-participant average among 20 other Microbial Colonization trials with a reported enrollment target (100% lower).

The record links to 1 condition, with Microbial Colonization appearing as the primary indexed condition, and to 1 intervention - of which Omadacycline Injection is the first listed.

NCT05515562 reports a single indexed study location in North Carolina.

Frequently Asked Questions

What is clinical trial NCT05515562 about?

NCT05515562 is a clinical study titled "Effects of Intravenous (IV) Omadacycline on Gut Microbiome". Given the clinical need to improve upon current antibiotic regimens for the treatment of C. difficile infection with a particular focus on the impact of therapies on gut microbiome, this study proposes to characterize the impact of Intravenous (IV) omadacycline on gut microbiome of healthy volunteer...

What is the current status of trial NCT05515562?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 8 participants. The study started on 2023-03-20. Estimated completion is 2023-07-11.

What conditions does trial NCT05515562 study?

This clinical trial studies the following conditions: Microbial Colonization.

What interventions are being tested in trial NCT05515562?

The interventions under investigation include: Omadacycline Injection (DRUG).

Who is sponsoring clinical trial NCT05515562?

This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05515562 being conducted?

This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Microbial Colonization

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05515562's enrollment target sits among peer trials

8 21st of 20 the lowest of 20 other Microbial Colonization trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Microbial Colonization trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05515562, the US trial registry maintained by the National Library of Medicine. NCT05515562 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.